
Pharma 4.0 – the Key Enabler for Successful Digital Transformation in Pharma
Part 1: Building a Business Case for Pharma 4.0
Part 1: Building a Business Case for Pharma 4.0
Symeres has appointed Gabriella Gentile as Chief Operating Officer to lead global operations and drive transatlantic growth, leveraging her extensive experience in the pharmaceutical and biotech sectors.
New state-of-the-art active pharmaceutical ingredient (API) facility in North Chicago will manufacture immunology, oncology, and neuroscience medicines.
October 15, 2025 | Join us for a dynamic virtual event where science meets strategy.
Dinamiqs, a Siegfried company specialized in viral vector design and manufacturing, inaugurated its new cGMP manufacturing facility.
Lilly plans to build a new $6.5 billion facility to manufacture active pharmaceutical ingredients in Houston, Texas.
Pfizer to acquire Metsera, a New York, NY-based clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and cardiometabolic diseases.
Prange Pharma is taking over a production site from MSD Animal Health in Aprilia, Italy. A new center for contract manufacturing in the field of animal health products is to be established there.
Acquisition supports Roche’s strategy as it enhances the company’s portfolio in cardiovascular, renal, and metabolic diseases (CVRM) and offers optionality for future combination development.
Includes $1.2 billion in manufacturing facilities, AI, and advanced digital technologies, creating hundreds of highly skilled US jobs.
The pharmaceutical industry has faced significant margin pressures due to rising energy costs, inflation, and geopolitical disruptions.
Asahi Kasei Life Science emerges as a new growth driver, uniting bioprocess solutions, CRO, and CDMO services to shape the future of healthcare under President Ken Shinomiya’s leadership.
Amid global uncertainty, Bayer Pharma, led by Stefan Oelrich, pursues strategic transformation to boost resilience, drive innovation, and secure sustainable growth in a changing healthcare landscape.
LGC Group has inaugurated a CAD$100 million (€61.5 million) Organic Chemistry Synthesis Centre of Excellence in Vaughan, Canada.
Novo Nordisk announced a global workforce reduction of approximately 9,000 positions to streamline operations and reinvest DKK 8 billion (€1 billion) in growth opportunities for diabetes and obesity treatments.
How pharma & biotech company transformed warehouse capacity planning for strategic growth
CRDMO Symeres has acquired DGr Pharma, expanding its capabilities with DGr Pharma’s regulatory and consultancy expertise to provide more comprehensive drug development services.
New Bay Area building marks significant progress as part of Gilead's $32 billion US investment.
The $700 million project is part of Genentech and Roche’s $50 billion investment in U.S. manufacturing, infrastructure and R&D
Gilgamesh's lead asset, bretisilocin (GM-2505), is a potential best-in-class psychedelic compound currently in Phase 2 development for the treatment of major depressive disorder (MDD).
AstraZeneca recently announced $50 billion of investment in the US by 2030. This investment is expected to create tens of thousands of new, highly skilled jobs nationwide.
Vetter broke ground for the start of construction of its new clinical site in Des Plaines, Illinois, US on June 26.
IMCD, a global partner for the distribution and formulation of speciality chemicals and ingredients, has acquired Trichem, an Indian pharmaceutical supplier.
Mabion, a biotech-focused CDMO offering end-to-end services, has announced the launch of a €500,000 oncology services contest at BIO International Convention 2025.
BASF has opened a new Good Manufacturing Practice (GMP) Solution Center in Wyandotte, Michigan, to support the supply of bioprocessing ingredients and excipients for the biopharma and pharmaceutical industries.
Brenntag recently announced the acquisition of Mcepharma to strengthen Brenntag’s capabilities across the entire pharmaceutical and biopharmaceutical value chain.
Sanofi to acquire Vigil Neuroscience, a clinical-stage biotech focused on therapies for neurodegenerative diseases.
Siegfried announced a further expansion of its ophthalmic drug manufacturing site in El Masnou near Barcelona, Spain.
The environment for pharma in 2025 is diverse and challenging: New treatment options are being brought to market in ever shorter cycles.
Leading the Way in Pharmaceutical Manufacturing by Fostering an Agile Mindset and an Inclusive Culture.
In an interview with CHEManager, Edgardo Hernandez, President of Lilly Manufacturing, explains the strategy behind the ambitious investment project.
Thermal hoods, boxes, cooling elements, data loggers: Ecocool supplies suitable equipment for GDP-compliant transportation of temperature-sensitive pharmaceuticals.
The Covid pandemic and its repercussions have changed the pharmaceutical industry and the healthcare markets. Richard Stedman, the CEO of ACG Engineering, discusses the lessons learned from the global supply chain disruptions and how innovative equipment helps pharma manufacturers overcome the challenges.
Biopharma companies are facing funding challenges in 2023 as interest rates rise and investors are becoming more risk adverse. There is hope on the horizon, say some analysts, while others project a prolonged slump due to inflation and global instability. Established pharmaceutical companies are often seen as safer investments, with larger developers expected to perform well in 2023, especially if litigation threats against drugs like Zantac disappear. However, concerns about revenue gaps continue for big companies like GSK and Sanofi, and their strategy and leadership will be closely monitored in the coming months.
As part of what seems to be a general pattern of staff reductions in the pharmaceutical industry worldwide, a growing number of Western drugmakers are downsizing their sales and marketing presence in India.